Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV9202
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CV9202 is a self-adjuvanting mRNA-based cancer vaccine designed to induce an immune response against non-small cell lung cancer (NSCLC). It consists of six mRNAs encoding tumor-associated antigens commonly overexpressed in NSCLC, specifically NY-ESO-1, MAGEC1, MAGEC2, 5T4, survivin, and MUC1. The vaccine is administered intradermally and aims to stimulate both humoral and cellular immune responses against these antigens. Developed using CureVac's RNActive technology platform, CV9202 is being advanced by Boehringer Ingelheim in collaboration with CureVac, Ludwig Institute for Cancer Research, and the Cancer Research Institute. Its primary indication is for the treatment of non-small cell lung cancer as part of immunotherapy regimens.
- Other names
- RNActive cancer vaccinemRNA-derived lung cancer vaccine
02
Targets
BIRC5 (Survivin)MUC1 (Mucin-1 Antigen)MAGEC1 (Melanoma antigen family C1)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)MAGEC2 (Melanoma-associated antigen C2)
Beyond the preview
Go deeper on CV9202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CV9202.